
    
      In comparison to placebo-augmented cognitive behavioral therapy (CBT),
      D-cycloserine-augmented CBT will lead to a greater reduction in both short-and long-term
      point prevalence abstinence as well as time to first smoking lapse and time to smoking
      relapse.
    
  